Drugs / IPH4502
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06781983 | Jan 2025 → Apr 2028 expected | — | Innate Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 6
| Date | Issuer | Release |
|---|---|---|
| 2026-07-21 | Innate Pharma | Results Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC) innate-pharma.com ↗
Preliminary anti-tumor activity continues to be observed in heavily pre-treated patients with advanced solid tumors, with objective responses reported in UC post enfortumab vedotin, as well as in NSCLC and HNSCC. |
| 2026-03-26 | Innate Pharma | Results Innate Pharma reports full year 2025 financial results and business update innate-pharma.com ↗
IPH4502 (Nectin-4 ADC) shows preliminary anti-tumor activity with favorable safety profile to date; Phase 1 cohort enrichment ongoing at active dose levels |
| 2025-04-29 | Innate Pharma | Results Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting innate-pharma.com ↗
IPH4502 demonstrated superior preclinical anti-tumor activity compared to enfortumab vedotin (EV) in urothelial carcinoma models with low or heterogeneous Nectin-4 expression, as well as in models resistant to EV. |
| 2025-03-26 | Innate Pharma | Results Innate Pharma highlights antibody drug conjugate IPH4502 abstract selected for the AACR 2025 annual meeting innate-pharma.com ↗
IPH4502 demonstrated preclinical anti-tumor efficacy in models of primary and acquired resistance to enfortumab vedotin and in tumors with low to moderate levels of Nectin-4 expression, extending its potential beyond urothelial carcinoma. |
| 2024-11-13 | Innate Pharma | Regulatory Innate Pharma reports Third Quarter 2024 Business Update and Financial Results innate-pharma.com ↗
We achieved notable regulatory milestones during the quarter including encouraging initial feedback from the FDA for lacutamab’s development plans and the IND approval for IPH4502, our nectin-4 ADC, which paves the way for its entry into clinical development. |
| 2024-09-23 | Innate Pharma | Regulatory Innate Pharma announces FDA clearance of the IND for IPH4502, a Nectin-4 ADC to be developed in solid tumors innate-pharma.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPH4502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06781983 ↗ |